Legend Biotech’s Carvykti Achieves USD 439 Million in Q2 2025 Sales
China-based Legend Biotech Corporation (NASDAQ: LEGN) reported that sales of Carvykti reached USD 439 million...
CAR-T
IASO Biotherapeutics Receives Orphan Drug Designation in South Korea for Fucaso in Multiple Myeloma
China-based IASO Biotherapeutics announced that its BCMA-targeted chimeric antigen receptor (CAR) T cell therapy, Fucaso...
AbbVie to Acquire Capstan Therapeutics for Its First-in-Class CAR-T Candidate
US-based pharmaceutical giant AbbVie (NYSE: ABBV) is poised to acquire fellow American firm Capstan Therapeutics,...
BMS Secures FDA Approval for Updated Labels of Breyanzi and Abecma
US major Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the US Food and Drug Administration...
FDA Removes REMS Requirements for BCMA- and CD19-Targeted CAR-T Therapies
The U.S. Food and Drug Administration (FDA) last week announced the removal of Risk Evaluation...
Porton Advanced Partners With EVA Pharma to Boost CAR-T Cell Therapy in MENA
China-based Contract Development and Manufacturing Organization (CDMO) Porton Advanced Solutions Ltd. has entered into a...
Legend Biotech Plans to Disband China Sales Team Amid Carvykti Commercialization Challenges
Reports indicate that China-based Legend Biotech Corporation (NASDAQ: LEGN) plans to disband its China sales...
JW Therapeutics’ Carteyva Approved by Macau Health Bureau
JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...
JW Therapeutics’ Carteyva Receives Fourth sBLA for r/r LBCL
JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...
AbelZeta Pharma’s C-CAR168 Secures FDA RMAT Designation for Lupus Treatments
Sino-US biotech AbelZeta Pharma, Inc., based in Rockville, Maryland, and with operations in Shanghai, announced...
CARsgen’s Satricabtagene Autoleucel Granted Priority Review by China’s CDE
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that the Center for Drug Evaluation...
CARsgen’s Satri-Cel Shows Significant Efficacy in Gastric Cancer Study
China-based CARsgen Therapeutics Holdings Limited (HKG: 2171) announced that it has published an abstract of...
BRL Medicine Reports Positive Results for TyU19 in Refractory SLE Trial
Shanghai-based BRL Medicine Inc. announced positive results from an investigator-initiated trial (ITT) evaluating its allogeneic...
CARsgen Therapeutics’ CT0596 Shows Promising Results in Early Clinical Study
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced preliminary clinical data for CT0596, an allogeneic...
IASO Biotherapeutics’ Fucaso Granted Orphan Drug Designation by SFDA for Multiple Myeloma
China-based IASO Biotherapeutics announced that the Saudi Food and Drug Authority (SFDA) has granted Orphan...
Oricell Partners with Umoja Biopharma to Develop In Vivo CAR-T Cell Therapies
China-based Oricell Therapeutics Co., Ltd. announced a strategic partnership agreement with US-headquartered Umoja Biopharma Inc....
BMS Q1 2025 Results: Opdivo Sales Up 12% Despite Overall Revenue Decline
US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) released its Q1 2025 financial results, showing a...
Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r/r B-ALL Trials
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with...
Juventas Cell Therapy’s CNCT 19 Gains NMPA Approval for Refractory Lupus Nephritis
China-based Juventas Cell Therapy Ltd announced that its chimeric antigen receptor (CAR)-T cell therapy, inaticabtagene...
JW Therapeutics Enters Licensing Pact with Juno Therapeutics for sLVV Process
China-based JW Therapeutics (HKG: 2126), co-founded by Juno Therapeutics Inc. (a Bristol-Myers Squibb company) and...